Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction.
BACKGROUND
The balance between pro-inflammatory and anti-inflammatory molecules is likely to modulate the processes that lead to atherogenesis and rapid coronary artery disease progression. We sought to compare the positive predictive values of serum soluble CD40 ligand (sCD40L)/interleukin-10 (IL-10) ratio, versus individual sCD40L, and IL-10 measurements regarding in-hospital events in patients admitted into the hospital with ST-segment elevation myocardial infarction (STEMI).


METHODS
We recruited 96 patients with STEMI. sCD40L and IL-10 were measured at hospital admission in every patient. The composite of in-hospital death and heart failure represented the study end-point. Heart failure was defined as Killip class>1. Multivariable logistic regression analysis was performed to identify independent variables related to in-hospital events.


RESULTS
Thirty two patients (33%) achieved the study end-point and 64 (67%) had no adverse events during hospital admission. IL-10 levels (pg/ml) were lower (28.2+/-9.8 versus 33.24+/-11.3, p=0.03) and sCD40L levels (pg/ml) higher (156.8+/-54.2 versus 135.4+/-38.70, p=0.02) in patients with events compared to those without events. Significantly higher odd ratios were found for sCD40L/IL-10 ratio (OR=2.10, 95% CI: 1.90 to 2.80, p=0.01) compared to individual sCD40L (OR=1.40, 95% CI: 0.90 to 2.20, p=0.08) and IL-10 (OR=0.70, 95% CI: 0.50 to 0.93, p=0.02) measurements.


CONCLUSIONS
Our study showed that serum ratio of sCD40L/IL-10 is a better independent predictor of in-hospital adverse events than individual sCD40L and IL-10 measurements in patients with STEMI.
Dominguez-Rodriguez
Alberto
A
Department of Cardiology, Coronary Care Unit, Hospital Universitario de Canarias, Tenerife, Spain. adrvdg@hotmail.com
Abreu-Gonzalez
Pedro
P
Garcia-Gonzalez
Martín J
MJ
Kaski
Juan Carlos
JC
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D023201:CD40 Ligand / Q000097:blood*; D015331:Cohort Studies; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000209:etiology / Q000276:immunology; D006760:Hospitalization; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood / Q000276:immunology; D016753:Interleukin-10 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications / Q000276:immunology / Q000503:physiopathology; D011237:Predictive Value of Tests; D011379:Prognosis; D012995:Solubility
D015415:Biomarkers; C508609:IL10 protein, human; D018836:Inflammation Mediators; D016753:Interleukin-10; D023201:CD40 Ligand